Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma

Kübra Altinel, Osuke Hashimoto, Yu Wei, Christine Neuveut, Ishita Gupta, Ana Maria Suzuki, Alexandre Dos Santos, Pierrick Moreau, Tian Xia, Soichi Kojima, Sachi Kato, Yasuhiro Takikawa, Isao Hidaka, Masahito Shimizu, Tomokazu Matsuura, Akihito Tsubota, Hitoshi Ikeda, Sumiko Nagoshi, Harukazu Suzuki, Marie-Louise Michel, Didier Samuel, Marie Annick Buendia, Jamila Faivre, Pierre Carninci

Riken Center for Life Science Technologies, Division of Genomic Technologies, Yokohama, Kanagawa, Japan; Laboratoire de Pathogenèse des Virus de l’Hépatite B, Institut Pasteur, Paris, France; Hepacivirus et Immunité Innée, UMR CNRS 3569, Institut Pasteur, Paris, France; INSERM, U1193, Paul-Brousse Hospital, Hepatobiliary Centre, Villejuif, France; Université Paris Sud, Faculté de Médecine Le Kremlin Bicêtre, Villejuif, France; Riken Center for Life Science Technologies, Division of Bio-Function Dynamics Imaging, Wako, Saitama, Japan; Department of Internal Medicine, Iwate Medical University, Iwate, Japan; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan; Department of Laboratory Medicine, Jikei University School of Medicine, Tokyo, Japan; Research Center for Medical Science, Jikei University School of Medicine, Tokyo, Japan; Department of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan; Department of Gastroenterology and Hepatology Saitama Medical Center, Saitama Medical University, Saitama, Japan; Assistance Publique-Hôpitaux de Paris, Pôle de Biologie Médicale, Paul-Brousse Hospital, Villejuif, France

ABSTRACT

Hepatitis B virus (HBV) is a major cause of liver diseases, including hepatocellular carcinoma (HCC), and more than 650,000 people die annually due to HBV-associated liver failure. Extensive studies of individual promoters have revealed that heterogeneous RNA 5' ends contribute to the complexity of HBV transcriptome and proteome. Here, we provide a comprehensive map of HBV transcription start sites (TSSs) in human liver, HCC, and blood, as well as several experimental replication systems, at a single-nucleotide resolution. Using CAGE (cap analysis of gene expression) analysis of 16 HCC/nontumor liver pairs, we identify 17 robust TSSs, including a novel promoter for the X gene located in the middle of the gene body, which potentially produces a shorter X protein translated from the conserved second start codon, and two minor antisense transcripts that might represent viral noncoding RNAs. Interestingly, transcription profiles were similar in HCC and nontumor livers, although quantitative analysis revealed highly variable patterns of TSS usage among clinical samples, reflecting precise regulation of HBV transcription initiation at each promoter. Unlike the variety of TSSs found in liver and HCC, the vast majority of transcripts detected in HBV-positive blood samples are pregenomic RNA, most likely generated and released from liver. Our quantitative TSS mapping using the CAGE technology will allow better understanding of HBV transcriptional responses in further studies aimed at eradicating HBV in chronic carriers.

IMPORTANCE

Despite the availability of a safe and effective vaccine, HBV infection remains a global health problem, and current antiviral protocols are not able to eliminate the virus in chronic carriers. Previous studies of the regulation of HBV transcription have described four major promoters and two enhancers, but little is known about their activity in human livers and HCC. We deeply sequenced the HBV RNA 5' ends in clinical human samples and experimental models by using a new, sensitive and quantitative method termed cap analysis of gene expression (CAGE). Our data provide the first comprehensive map of global TSS distribution over the entire HBV genome in the human liver, validating already known promoters and identifying novel locations. Better knowledge of HBV transcriptional activity in the clinical setting has critical implications in the evaluation of therapeutic approaches that target HBV replication.
tor protein (7–9). Heterogeneous 5' ends and in-frame ATG codons play important roles in increasing the diversity of proteins made from a small genome. For example, two 3.5-kb mRNAs are transcribed from the core promoter with slightly different transcription start sites (TSSs); one containing the preC start codon is named precore mRNA, translated into the precore protein and giving rise to the e antigen, and the other missing this start codon is called pgRNA, which is translated into the core and polymerase proteins, in addition to serving as a template for viral DNA replication (8, 10). In addition, two 2.1-kb mRNAs are transcribed from the S promoter with 5' heterogeneity; one TSS containing the preS2 start codon is for MHBs, and the other downstream the preS2 start codon is for the SHBs (11). The exact positions of TSSs for individual promoters have been studied using 5' RACE (rapid amplification of cDNA ends) and an RNase protection assay; however, how frequently each start site is used in different hosts and conditions is not well understood. In addition, analysis of the numerous TSSs in the HBV genome requires high-throughput technologies for comprehensive mapping in a quantitative manner.

Cap analysis of gene expression (CAGE), a method for genome-wide identification of TSSs, is focused on the selective capture of the capped 5' ends of RNAs (cap trapping). It is based on the principle that the cap site and the 3' end of mRNA are the only sites carrying the diol structure that can be chemically labeled with a biotin group. By using streptavidin-coated magnetic beads, only the full-length first-strand cDNA/mRNA hybrids are selectively recovered after RNase I treatment. Sequencing short sequence reads (or tags) taken from the 5' ends of full-length cDNAs allows TSSs to be mapped and their expression, measured by tag frequency, to be analyzed (12, 13). The CAGE technology has been extensively used to identify exact positions of TSSs in various different organisms from mammals to viruses (14–16). CAGE has also shown high reproducibility for expression measurements through a number of large scale projects, including FANTOM (17, 18) and ENCODE (19), discovering novel noncoding RNAs (ncRNAs) and transcribed enhancers (20). Because the HBV genome is entirely coding, with extensive overlap of the viral genes, quantification of individual transcripts by RNA-Seq is not feasible. Here, we used the CAGE technology for quantitative mapping of TSSs on the whole HBV genome at a single-nucleotide resolution. We analyzed the HBV transcriptome in chronically infected human livers and HCCs that we collected and sequenced in a previous study (21) and in whole blood from HBV-positive patients, as well as several experimental models of HBV replication. To our knowledge, our data provide the most comprehensive map of quantitative TSSs as a resource to study transcriptional activity of HBV in experimental setting and design new therapeutic approaches for inhibiting HBV replication in chronically infected patients.

**MATERIALS AND METHODS**

**CAGE libraries for human liver tissues.** CAGE libraries for human liver tissues were prepared and sequenced as detailed in our previous study (21). Raw data are available through the NCBI dbGaP database (22) under accession number phs000885.v1.p1 (controlled access). Briefly, liver tissues, including tumor and nontumor samples, were collected from patients resected for HCC (Table 1; see also Table S1 [c18 http://gerg.gsc.riken.jp/JVI2016/SupplementaryMaterials.pdf]). CAGE libraries were prepared according to a published protocol (12) and sequenced with single-end reads of 50 bp on an Illumina HiSeq 2000 platform. The ethics evaluation committees of the INSERM (IRB00003888, FWA00005041) and RIKEN (H24-4) approved the use of human liver samples. All patients provided written informed consent.

**CAGE libraries for human blood and HBV model systems.** The ethics review committee of Saitama Medical University approved the use of human blood samples. Blood samples were collected from male HBV (genotype C) positive patients who did not develop HCC. Total RNA was extracted from RNAlater (Ambion)-treated whole blood using the RiboPure-Blood kit (Ambion), followed by the RNeasy kit (Qiagen), for further purification. CAGE libraries were prepared in accordance with the latest version of the protocol, which does not require a PCR amplification step (13), and were sequenced with single-end reads of 50 bp on the Illumina HiSeq 2000 platform.

**Determination of CAGE TSSs.** We mapped the CAGE tags to the human genome (hg19/GRCh37 assembly) or to the murine genome.

**TABLE 1 Clinical samples with serological HBV markers**

| Sample | Gender | Age (yr) | Predicted genotype | HBsAg status | HBeAg, HBeAg, and/or anti-HBe status | Antiviral treatment |
|--------|--------|----------|--------------------|--------------|-------------------------------------|--------------------|
| 1       | Male   | 47       | A G               | Positive     | Negative                            | Lamivudine and adefovir dipivoxil |
| 2       | Male   | 62       | E A               | Positive     | Anti-HBe positive                    | Tenofovir          |
| 3       | Male   | 56       | Negative          | Negative     | Anti-Hbc positive                    | No treatment       |
| 4       | Male   | 59       | D D               | Negative     | Anti-Hbc positive                    | No treatment       |
| 5       | Male   | 73       | D D               | Positive     | HBeAg positive                       | Adefovir dipivoxil |
| 6       | Female | 56       | D A               | Positive     | NA                                  | Lamivudine         |
| 7       | Male   | 54       | D E               | Positive     | NA                                  | NA                 |
| 8       | Male   | 38       | A A               | Positive     | Anti-HBc, anti-HBe positive          | Lamivudine         |
| 9       | Male   | 49       | D D               | Positive     | Anti-Hbc, anti-HBe positive          | No treatment       |
| 10      | Male   | 60       | E E               | Positive     | HBeAg positive                       | Adefovir dipivoxil |
| 11      | Male   | 47       | E E               | Positive     | NA                                  | Lamivudine         |
| 12      | Male   | 58       | C C               | Positive     | HBeAg positive                       | Lamivudine         |
| 13      | Male   | 73       | D D               | Positive     | NA                                  | NA                 |
| 14      | Male   | 72       | A A               | Negative     | Anti-HBc positive                    | No treatment       |
| 15      | Male   | 55       | A A               | Positive     | HBeAg positive                       | Lamivudine, adefovir dipivoxil, and tenofovir |
| 16      | Male   | 66       | C C               | Positive     | Anti-Hbc positive                    | Lamivudine and adefovir dipivoxil |

* HBcAg, HBeAg, HBeAg, and anti-HBe were measured in serum. NA, data not available.
(mm9/NCBI37 assembly) in the case of the murine liver transduced with AAV-HBV, using BWA v0.5.9 (23) with default parameters on the MOIRA pipeline (24). The unmapped tags extracted from the mapping results were aligned to 16 representative HBV genomes downloaded from HBVdb (25). Because the HBV genome is circular, each genome was randomly repeated for mapping all genome sequences. After alignment of tag sequences with 16 representative HBV genomes, the HBV genotype in each sample was defined as the genome to which the highest tag counts were mapped. To unify the genomic positions of HBV, an HBV genome sequence (accession number GQ358158.1 in GenBank) with genotype C and genome size: 3,215 bp was selected as a reference genome. The genomic positions for the other genomes were converted to those of the reference genome based on multiple alignments of HBV genomes. CAGE technology often adds an extra G base to the 5’ end in the reverse transcription process (26). To correct one base shift of the 5’ end, the first mismatched G was removed. We then clustered the tags to define distinct CAGE peaks using Paraclu with the following parameters: (i) a minimum of 100 total tags per cluster, (ii) a minimum density increase of 2, and (iii) a maximal cluster length of 100 bp (27). Paraclu was designed to identify CAGE TSS peaks and is commonly used in studies using CAGE such as ENCODE. The algorithm calculates densities of CAGE tags and finds maximal segments where every prefix and suffix of the segment has a given density. Raw tag counts for each peak were divided by a total tag count of the library, including human transcriptome, to calculate normalized expression values. The unit of the expression value is tpm, i.e., tags per million mapped million tags. CAGE tags and peaks were visualized using IGV (28).

Cells. The HepAD38 cell line is derived from HepG2 cells and contains the HBV genome (subtype ayw) under tetracycline control (29). HepAD38 cells were maintained in Dulbecco modified Eagle medium/F-12 with 10% fetal calf serum (FCS), 3.5 × 10⁻² M hydrocortisone hemisuccinate, and insulin at 5 μg/ml. Primary human hepatocytes (PHHs) were purchased from Corning (catalog number 454541, lot number 399) and maintained in PHH medium (Corning catalog number 355056, Corning hepatocyte culture media kit, 500 ml) as recommended by the manufacturer.

Virus production and infection of primary human hepatocytes. For virus production, HepAD38 cells were grown in Williams E medium with 5% FCS, 7 × 10⁻⁵ M hydrocortisone hemisuccinate, insulin at 5 μg/ml, and 2% dimethyl sulfoxide. HBV particles were concentrated from the clarified supernatant by overnight precipitation with 5% PEG 8000 and centrifugation at 4°C for 60 min at 5,000 rpm. Titers of enveloped DNA-containing viral particles were determined by immunoprecipitation with an anti-preS1 antibody (kindly provided by C. Sureau), followed by qPCR quantification of viral RC DNA with the following primers: RC5’ (5’-CATCTATGGAAGCGGCTC-3’) and RC3’ (5’-TGTCCTCA GCTCCTACCTGTTG-3’) (30). Around 20 to 25% of HBV DNA measured in the cell supernatant was recovered in the preS1 immunoprecipitate, correlating with the finding of 25% of enveloped virions and 75% of naked capsids by using native agarose gel electrophoresis, transfer onto nitrocellulose, and hybridization with radiolabeled HBV probe and anti-HBs antibody as previously described (31). For infection, only enveloped DNA-containing viral particles (vp) were taken into account to determine the multiplicity of infection (MOI). PHHs were infected as previously described with normalized amounts of virus at an MOI of 500 vp/cell (32).

Animal experiments. The AAV-HBV vector has been described previously (33). Six-week-old FVB/NCr1 male mice obtained from The Jackson Laboratory received a single tail vein injection of 5 × 10¹⁰ viral genomes (vg) of AAV-HBV vector or control vector AAV-GFP. Mice were sacrificed at 20 weeks postinjection. Total RNA was extracted from mouse livers with TRI Reagent (Sigma-Aldrich). The experimental procedures were approved by the Institut Pasteur (CHSCT 10.289), in accordance with French government regulations. Mice were bred in a pathogen-free environment at the Institut Pasteur animal facility in accordance with welfare criteria outlined in the Guide for the Care and Use of Laboratory Animals.

Northern blot analysis. Portions (20 μg) of total RNA was denatured by formaldehyde, run on 1% agarose gels in 20 mM phosphate (pH 7.0) and 1% formaldehyde, and blotted onto Hybond N+ in 20X SSC (1X SSC is 0.15 M NaCl plus 0.015 M sodium citrate). A DNA fragment covering the HBV genome was used as probe. DNA labeling and hybridization were performed using a DIG High Prime DNA labeling and detection starter kit II (Roche). DNA sizes were estimated according to a molecular weight ladder (RNA molecular weight marker 1, DIG labeled; Sigma-Aldrich).

Accession number(s). Supplementary materials are accessible at http://greg.gsc.rikene.jp/JVI2016/SupplementaryMaterials.pdf. CAGE data for human HCC samples were released in the NCBI database of Genotypes and Phenotypes (dbGaP; http://www.ncbi.nlm.nih.gov/gap/) under accession number phs000885.v1.p1. CAGE data for human blood samples were released in the NBDC human database (http://humanbds.biosciencedbc.jp/en/) under hum0050. CAGE data for HBV model systems were released in the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE84186.

RESULTS AND DISCUSSION

Variable expression of HBV transcripts in human livers and HCC. We have recently described CAGE analysis of human transcriptome in HCC and nontumor livers (21). Among analyzed cases, 16 pairs of tumor (T) and nontumor (NT) liver samples from HBV-positive HCC patients were selected for further studies of the HBV transcriptome (Table 1; see also Table S1 [c18 http://greg.gsc.rikene.jp/JVI2016/SupplementaryMaterials.pdf]) of CAGE tags that did not match human sequences, we identified a total of 376,770 tags that were mapped on the HBV genome using 16 representative HBV genomes curated by HBVdb (25) (see Table S2 in the supplemental material). Sequences from other viruses could not be found. HBV transcripts were detected in 30 of 32 samples with a 1 tag-per-million (tpm) threshold but not in HCV-associated samples used as controls. The expression levels of total HBV transcripts were highly variable in different samples from as low as TATA box binding protein (TBP) (median = 5.3 tpm) to as high as beta-actin (ACTB) (median = 1,128 tpm) (Fig. 1A). A high variability was observed also between T and NT samples from the same individual; for example, the expression value is 781 tpm in sample 8T and only 2.7 tpm in 8NT, the matched nontumor (Fig. 1B). It should be noted that most patients received antiviral treatment at the time of tumor resection (Table 1), which might account for low level of HBV transcription in a majority of samples, as previously reported (34). We then determined the closest genotype for each sample based on the counts of tags mapped on 16 HBV genomes across eight major genotypes (25). The determined genotypes with the highest tag counts were mostly A and D, which are known to be prevalent in Europe (Table 1). Despite a number of ambiguous sequence positions in the tags, we found evidence for different genotypes in four T/NT pairs, probably reflecting intergenotype dual infection of these patients as already reported in other studies (35).

We identified 17 robust TSSs (CAGE peaks) supported by at least 100 raw tag counts in total and expressed at least in 10 samples, of which six peaks supported by more than 1,000 raw tags were referred to as major peaks (Fig. 1C). Several known TSSs were correctly identified as major peaks by this method, including preS1 (peak 1), preS2 (peak 2), and pgRNA (peak 16). The TSS positions were either highly specific, especially for pgRNA at position 1818, 4 bp downstream of the preC start codon (7) (Fig. 2A),
or scattered over several positions as exemplified by the basal core promoter (BCP) region between positions 1740 and 1785, where the preC RNA TSS has been mapped previously (8, 10). In this study, the only recurrent TSS position in the BCP region was localized at nucleotides 1745 and 1746 (Fig. 2B). In a large majority of T and NT samples, pgRNA levels were 10-fold higher than other transcripts in the BCP. As expected, preS/S transcripts and pgRNA were predominant RNAs in all samples (Fig. 2C), although the percentages varied greatly between individual cases. Among the minor peaks, two antisense transcripts that could represent ncRNAs were detected at low levels of expression (see Fig. 1C). One of them started in the preC region, close to the core promoter (peak 17), and the second, transcribed from the middle of the X gene (peak 12) and detected in 14 samples, was previously reported as a minor nonpolyadenylated transcript (36). Note that CAGE can capture both poly(A)$^+$ and poly(A)$^-$ transcripts by using random primers. These minor antisense transcripts might be involved in the regulation of the neighboring promoters.

**Heterogeneous promoter usage for the S and X genes.** It is known that two independent promoters are responsible for producing three forms of the surface proteins (large, middle, and small). The first one, called the preS1 promoter, characterized by a canonical TATA box, is located upstream of the first start codon. The other one, called the preS/S promoter, is located in the preS1

---

**FIG 1** Quantification of HBV transcripts and comprehensive TSS map of HBV in chronically infected nontumor livers and HCCs. (A) Distribution of expression values for HBV transcripts and housekeeping genes in 15 tumor and 15 NT samples (sample 3 is excluded). The TATA box binding protein (TBP) and beta-actin (ACTB) genes are representatives of moderately and highly expressed genes, respectively. Expression data are derived from the same 15 HCC patients. (B) Relative HBV expression levels between tumor and matched nontumor samples. The relative value of 0.5 indicates that HBV expression levels are the same in T and NT. Samples are sorted by tumor ratios. (C) Distribution of detected CAGE peaks in the HBV genome. Large and small arrows on the outer circle indicate major CAGE peaks supported by $>$1,000 tags and minor peaks supported by 100–1,000 tags. Arrows inside the circle represent open reading frames for four HBV genes. Genomic coordinates in the right panel correspond to the representative genome (GQ358158.1), where the EcoR1 site is the first position (1). "Model" in the tables indicates whether the peak is present in HBV replication model systems (see Fig. 6 and see Table S6 in the supplemental material).
HBV Transcription in the Human Liver

FIG 2 TSSs distribution in the basal core promoter (BCP) region in nontumor liver and HCC. (A) Major peaks for preC and pgRNA, showing a predominant peak for pgRNA (peak 16) at position 1818, and scattered minor peaks over the BCP region. The scale shown at the right represents the maximal tag counts in each sample. (B) Recurrent TSS for preC RNA (peak 15). The TSS shape from pooled samples is shown in the lower panel. (C) Relative expression levels of the preS/S transcripts, pgRNA, and others in T (left panel) and NT samples (right panel).

region, and it is devoid of a TATA box, which enables to generate two types of mRNAs, initiated either upstream or downstream of the preS2 start codon, and giving rise to the middle protein or the small protein using the third start codon (11). In addition to the preS1 promoter (peak 1) and the preS2/S promoter (peak 2), we identified an extra major promoter (peak 3) for the small protein (Fig. 3A). This potential novel promoter is characterized by an enriched TSS at position 111, immediately downstream of the preS2/S promoter, and it gives broad but weak signals (Fig. 3B). The expression level of this promoter is as high as the preS1 promoter, but much lower than the preS2/S promoter except for 1T and 2NT samples (Fig. 3A). Due to the predominant expression of the preS2/S promoter in a large majority of samples, the ratio of middle to small surface proteins depends on the TSS usage within this promoter. As reported in previous studies, we observed heterogeneous 5’ ends distributed upstream and downstream of the ATG but, more importantly, these TSSs are not equally used in different samples. Interestingly, our quantitative TSS mapping shows at least three distinct patterns of the TSS usage depending, at least in part, on the HBV genotype. The first group (genotype D) has the most frequent start site at nucleotide 3190 with weaker signals at nucleotides 3212, 5, 7, and 18. The second group (genotype A) has the strongest signal at nucleotide 3212 with a weaker signal at 3190, and the third group (mostly genotype E) has the

December 2016 Volume 90 Number 23 jvi.asm.org

Journal of Virology

jvi.asm.org 10815
strongest signal at nucleotides 5 or 7, with weaker signals at nucleotides 3190 and 3212 (Fig. 3B).

Unlike the S gene, the X gene is widely believed to produce a single form of protein (17-kDa X protein or HBx) translated from a 0.7-kb mRNA. This protein is required for HBV replication in vivo and functions as a broad-range transactivator that stimulates the expression of viral and cellular genes (37–39). We identified a faint peak upstream of the first ATG of the X gene (peak 10, TSS for the middle protein).
HBV transcription and replication are reduced in tumors compared to liver. As shown in Table S3 in the supplemental data (c18 http://gerg.gsc.riken.jp/JVI2016/SupplementaryMaterials.pdf), predominant TSSs in HCCs were found for the preS2/S promoter (peak 2), followed by the core (peak 16), preS1 (peak 1) and S promoters (peak 11). Although the average activity of the preS2/S promoter was similar in T and NT livers, the average transcription from the preS1, core, and X promoters was ~4-fold lower in HCCs. This might reflect the strict requirement of these promoters for liver-enriched transcription factors, in contrast to the preS2/S promoter regulation by ubiquitous factors (43). Presently, it is not possible to determine whether viral RNAs detected in HCC are produced from integrated HBV sequences or from episomal cccDNA. However, the TSS positions in HCCs were almost identical to those in NT livers, and we observed in most tumors a robust pgRNA TSS at position 1818, a region frequently disturbed by host-viral junctions upon HBV integration (44), suggesting that transcription might occur from the HBV cccDNA as well as integrated HBV sequences, which might contribute to HBV recurrence after liver transplantation (45).

**HBV transcriptome in blood.** The HBV genome is generally considered to be transcribed only in liver, but viral RNAs are frequently found in the sera of HBV-infected patients (46). To better characterize these HBV RNA species, we sequenced new CAGE libraries for eight whole-blood samples derived from HBV genotype C-positive patients, independent of the first patient group (Fig. 5A). CAGE tags aligned to the HBV genome (GQ358158.1, a representative genotype C) were detected from all samples, ranging from 40 to 2,500 tpm. The level of transcripts is significantly correlated with the level of HBsAg in blood (Spearman’s correlation coefficient = 0.762 and P = 0.037) (Fig. 5B). Comparison of TSS positions with the 17 peaks identified in liver tissues showed a

---

**Fig. 4A**, corresponding to a part of the canonical X promoter (9). Surprisingly, we identified a higher peak between the first and the second ATG (peak 11), which shows moderate expression levels in a subset of samples (Fig. 4A). The transcription starts preferentially at nucleotide 1524 in tumors and nontumor livers (Fig. 4B). Note that although the cap selectivity of the CAGE technology is very high (ca. 333- to 625-fold enrichment for capped RNAs [26]), it is still possible to have artificial peaks on cleavage hot-spots produced by massive amounts of site-specific cleavage events. Nevertheless, a recent study using covalently closed circular DNA (cccDNA) ChIP-Seq approach has shown two distinct peaks of active promoter marks (H3K4me3, H3K27ac, and H3K122ac) within the X gene body, especially prominent in HBV-infected primary human hepatocytes and HBV-positive liver tissues (40). The second histone modification peak located at the middle of the X gene might be associated with the new TSS detected here. Moreover, analysis of the conservation of X gene in-frame ATGs using 6,949 nucleotide sequences across eight genotypes showed that the second ATG is as well conserved as the first ATG (99.6% for both), whereas the third ATG is slightly less conserved (94.0%). It has been shown previously that the X gene is able to produce shorter transcripts (41, 42). Collectively, these data indicate that the potential novel transcript evidenced by CAGE might give rise to a shorter HBx protein retaining transactivator function to regulate viral and host genes.

**Comparison of TSS usage between HCCs and nontumor livers.** HBV expression levels were highly heterogeneous in HCC samples, with total counts ~2-fold lower than those for nontumor liver samples (no significant difference, P = 0.7437, Wilcoxon rank-sum test). These data are in agreement with the notion that

---

**FIG 4** TSSs in the X gene region at a single-nucleotide resolution. (A) Expression values of the new TSS located inside the X gene (peak 11) and the canonical TSS upstream of the X gene (peak 10). (B) TSSs distribution between the first and second ATGs of the X gene for six tumors and seven nontumors in which the expression values are >1 tpm. The conservations of the three ATG among 6,949 nucleotide sequences from different HBV genotypes are 99.6% (6,919 of 6,949), and 94.0% (6,534 of 6,949).
high prevalence of TSS at position 1818, whereas few tags were mapped to the S promoters (Fig. 5C and D). This major start site is consistent with the pgRNA TSS found in tumor and liver samples (see Fig. 2A), as well as in previous studies (7). Thus, the predominance of pgRNA in blood samples suggests that immature capsids, in which HBV DNA replication has not been completed, might be released from liver into blood, as already observed in several reports (46–49). We have to consider another possibility, where CAGE captures the capped 5’ end of the pgRNA that survives as a short RNA fragment attached to the “+ polarity” DNA strand in HBV virions, although a majority of DNAs hybridized with short 5’ polarity DNA strands in HBV virions, although a majority of TSS peaks are shared in clinical and experimental samples. We identified 15 peaks, 10 of which overlap the clinical peaks for genotype D with some variable signals at bp 7 (Fig. 5D). Finally, we analyzed HBV RNA by Northern blotting in the model systems, instead clear signals were detected at around bp 1250, upstream of the 1st ATG, which can contribute to the full-length X protein (Fig. 6C). This suggests that HBV might use different promoters for two sizes of X proteins in different conditions (Fig. 6C), indicating that a majority of TSS peaks are shared in clinical and experimental conditions (Fig. 1C and see Table S6 in the supplemental material). On the other hand, a major difference was found in the basal core promoter region, in which the major peak 15 was not detected in the model systems, instead clear signals were detected between bp 1780 and 1800 (Fig. 6B), corresponding to previous report of the preC RNA start site (10). The relative expression of the region from bp 1780 to 1800 among model systems is similar to the preS/S (peak 2), where the AAV-HBV model is the highest. The X promoter also shows a different pattern from the clinical condition. In addition to peaks 10 and 11, another broad peak was detected at around bp 1250, upstream of the 1st ATG, which can contribute to the full-length X protein (Fig. 6C). This suggests that HBV might use different promoters for two sizes of X proteins in different conditions, although functional analysis such as reporter assays is essential for further understanding of the promoter usage. The preS/S promoter shows consistent pattern with the clinical peaks for genotype D with some variable signals at bp 7 (Fig. 6D). Finally, we analyzed HBV RNA by Northern blotting in

![FIG 5](http://jvi.asm.org/c18/)

Identification and quantification of HBV transcripts in blood. (A) List of human blood samples analyzed by CAGE. Samples were collected from male genotype C-positive patients with various HBsAg levels. (B) Association between RNA and HBsAg levels in blood. Each dot represents one blood sample. Both x and y axes are shown in log-scale. (C) Relative expression of detected RNAs in blood. About 87 to 95% of the tags are mapped within the pgRNA peak. “Outside” indicates tags mapped outside all 17 HBV peaks detected in the liver transcriptome. (D) Transcription start sites of the pgRNA in blood. The scale of the x axis is fit to the raw tag counts of each sample.

### Human Blood Samples

| #  | ID    | Age | Sex | HBsAg (IU/ml) | HBeAg (IU/ml) | HBeAb (%) | ALT (IU/L) | HBV-DNA (Log copy/ml) |
|----|-------|-----|-----|---------------|---------------|-----------|------------|------------------------|
| 1  | Blood-01 | 34  | Male | 70,200        | 160           | 0.1       | 49         | >9.0                   |
| 2  | Blood-02 | 44  | Male | 279,000       | 1,600         | 0.1       | 116        | >9.0                   |
| 3  | Blood-03 | 51  | Male | 34,600        | Positive      | Negative  | 50         | 9.1                    |
| 4  | Blood-04 | 32  | Male | 107,000       | 1,510         | <35       | 27         | >9.0                   |
| 5  | Blood-05 | 29  | Male | 4,070         | 996           | 0.1       | 481        | 8.4                    |
| 6  | Blood-06 | 27  | Male | 2,390         | 31            | 54        | 189        | 7.5                    |
| 7  | Blood-07 | 40  | Male | 6,570         | 778           | <35       | 43         | 9.0                    |
| 8  | Blood-08 | 33  | Male | 4,036         | Positive      | Negative  | 53         | 7.9                    |
FIG 6 Identification and quantification of HBV transcripts in model systems. (A) Expression values of total HBV, pgRNA (peak 16), preS/S (peak 2), and the new TSS inside the X gene (peak 11). (B) TSS distribution in the basal core promoter region. Detailed CAGE signals and expression values between bp 1780 and 1800 are shown in the right panel. (C) TSSs distribution in the X promoter region upstream and downstream of the first start codon. (D) TSSs distribution in the preS/S promoter region. (E) Northern blot analysis of HBV RNA. The total RNA (20 μg) from HepAD38 cells and from mouse livers transduced with either AAV-HBV vector (AAV-HBV) or control AAV-GFP vector (control) was analyzed by Northern blotting. For HepAD38 cells, the results for a shorter exposure are shown in the second lane. The sizes of major transcripts are indicated on the right.
two experimental models, including HepAD38 cells and mouse liver transduced with AAV-HBV to visualize major HBV transcripts. The data showing important differences in the relative levels of major transcripts (pgRNA and preS2/S RNA) between the two systems are in complete agreement with the CAGE data (Fig. 6E).

Conclusion. In this study, we used CAGE analysis to investigate the HBV transcriptome in nontumor liver, HCC, and blood from HBV-positive patients, as well as in four experimental HBV replication systems. This approach provided extensive and accurate positioning of all HBV TSSs, as well as quantitative evaluation of relative expression levels in the clinical setting. We also provide evidence for HBV transcriptional activity in tumor cells, although transcription template (episomal or integrated HBV sequences) cannot be ascertained by current technologies. A comprehensive and quantitative map of HBV transcripts in human tissues has not been described so far using conventional technologies, due to the compact structure of the HBV genome and the overlap of different open reading frames. Here, transcription from the four well-studied promoters (core, preS1, S, and X promoters) was correctly detected in the regions described in previous studies, with detailed information on relative TSS usage in the S and core promoter regions. In addition, 11 novel TSSs were discovered. One novel major TSS is located in the X gene body between the first and second start codons. Because of the high reproducibility of this transcription peak, its higher expression level compared to the canonical X transcript in nearly all clinical samples, and the strong conservation of the second ATG, we propose this transcript as a candidate mRNA that encodes a shorter form of the X protein. It has been reported that this short X protein might be endowed with transactivator functions similar to full-length HBx (42). We also detected minor, recurrent antisense TSSs in the core promoter and the X gene, which might represent ncRNAs implicated in the regulation of HBV transcription and could be used for therapeutic approaches based on selective inhibition of HBV transcription and replication. Current therapeutic regimens, the use of including nucleos(t)ide analogs such as lamivudine, potently inhibit viral replication but are not capable of eliminating the virus or controlling infection on the long-term after drug withdrawal because of frequent persistence of the HBV cccDNA within hepatocytes. Therefore, a potential therapeutic strategy to eradicate HBV could be to silence and eliminate cccDNA from infected cells. In this context, our study offers new tools for the characterization of HBV transcriptional responses in experimental setting.

ACKNOWLEDGMENTS

We thank RIKEN GeNAS for the sequencing of the CAGE libraries. This study was supported by the Seventh Framework Programme (FP7) under grant agreement 259743 (MODHEP consortium), as well as by a research grant from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT) to the RIKEN Center for Life Science Technologies. Y.T., I.H., M.S., T.M., A.T., H.I., S.N., and H.S. were funded by the Seventh Framework Programme (FP7) (259743). This work, including the efforts of Soichi Kojima, Yasuhiro Takikawa, Isao Hidaka, Masahito Shimizu, Tomokazu Matsuura, Akihito Tsubota, Hitoshi Ikeda, Sumiko Nagoshi, and Harukazu Suzuki, was funded by Japan Agency for Medical Research and Development (AMED).

FUNDING INFORMATION

This work, including the efforts of Kosuke Hashimoto, Ana Maria Suzuki, Soichi Kojima, Harukazu Suzuki, and Piero Carninci, was funded by Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (RIKEN CLST). This work, including the efforts of Soichi Kojima, Yasuhiro Takikawa, Isao Hidaka, Masahito Shimizu, Tomokazu Matsuura, Akihito Tsubota, Hitoshi Ikeda, Sumiko Nagoshi, and Harukazu Suzuki, was funded by Ministry of Health, Labour and Welfare (MHLW) (H24-B Drug Discovery-Hepatitis-General-003). This work, including the efforts of Kosuke Hashimoto, Yu Wei, Ana Maria Suzuki, Marie Annick Buendia, Jamila Faire, and Piero Carninci, was funded by EC | Seventh Framework Programme (FP7) (259743). This work, including the efforts of Soichi Kojima, Yasuhiro Takikawa, Isao Hidaka, Masahito Shimizu, Tomokazu Matsuura, Akihito Tsubota, Hitoshi Ikeda, Sumiko Nagoshi, and Harukazu Suzuki, was funded by Japan Agency for Medical Research and Development (AMED).

REFERENCES

1. El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264–1273. http://dx.doi.org/10.1053/j.gastro.2011.12.061.
2. Neuvect C, Wei Y, Buendia MA. 2010. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52:594–604. http://dx.doi.org/10.1016/j.jhep.2009.10.033.
3. World Health Organization. 2015. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. World Health Organization, Geneva, Switzerland.
4. Beck J, Nassal M. 2007. Hepatitis B virus replication. World J Gastroenterol 13:48–64. http://dx.doi.org/10.3748/wjg.v13.i1.48.
5. Schaef R, S. 2007. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13:14–21. http://dx.doi.org/10.3748/wjg.v13.i1.14.
6. Kramvis A. 2014. Genotypes and genetic variability of hepatitis B virus. Intervirology 57:141–150. http://dx.doi.org/10.1159/000360949.
7. Will H, Reiser W, Weimer T, Pfeil E, Buscher M, Sprengel R, Cattaneo R, Schaller H. 1987. Replication strategy of human hepatitis B virus. J Virol 61:904–911.
8. Quarleri J. 2014. Core promoter: a critical region where the hepatitis B virus makes decisions. World J Gastroenterol 20:425–435. http://dx.doi.org/10.3748/wjg.v20.i2.425.
9. Yajinuma K, Nakamura I, Takada S, Koike K. 1993. A transcription initiation site for the hepatitis B virus X gene is directed by the promoter-binding protein. J Virol 67:2559–2565.
10. Chen IH, Huang CJ, Ting LP. 1995. Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus. J Virol 69:3647–3657.
11. Siddiqui A, Jameel S, Mapoles J. 1986. Transcriptional control elements of hepatitis B surface antigen gene. Proc Natl Acad Sci U S A 83:566–570. http://dx.doi.org/10.1073/pnas.83.3.566.
12. Takahashi H, Lassmann T, Murata M, Carninci P. 2012. 5’ end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. Nat Protoc 7:542–561. http://dx.doi.org/10.1038/nprot.2012.005.
13. Murata M, Nishiyori-Sueki H, Kojima-Ishiyama M, Carninci P, Hayashizaki Y, Itoh M. 2014. Detecting expressed genes using CAGE. Methods Mol Biol 116:67–85. http://dx.doi.org/10.1007/978-1-4939-08085-9_7.
14. Forterre V, Hashimoto K, Yamada D, Salimullah M, Keya CA, Saxena A, Bonetti A, Voinaegiu I, Bertin N, Kratz A, Noro Y, Wong CH, de Hoon M, Andersson R, Sandelin A, Suzuki H, Wei CL, Koski H, Consortium F, Hasegawa Y, Forrest AR, Carninci P. 2014. Deep transcriptome profiling of mammalian stem cells supports a regulatory role for retrotransposons in pluripotency maintenance. Nat Genet 46:538–566. http://dx.doi.org/10.1038/ng.2965.
15. Forterre V, Li N, Hadzhiev Y, Plessy C, Previti C, Nepal C, Gehrig J, Dong X, Akalin A, Suzuki AM, van IW, Armant O, Ferg M, Strahle U, Carninci P, Muller F, Lenhard B. 2014. Two independent transcription initiation codes overlap on vertebrate core promoters. Nature 507:381–385. http://dx.doi.org/10.1038/nature12974.
16. Taguchi A, NagasaK K, Kawana K, Hashimoto K, Kusumoto-Matsuoi R, Plessy C, Thomas M, Nakamura H, Bonetti A, Oda K, Kubimoto I, Altin et al.
of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890–1899. http://dx.doi.org/10.1053/j.gastro.2008.02.064.

46. van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, Edelmann A. 2015. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61:66–76. http://dx.doi.org/10.1002/hep.27381.

47. Miller RH, Tran CT, Robinson WS. 1984. Hepatitis B virus particles of plasma and liver contain viral DNA-RNA hybrid molecules. Virology 139:53–63. http://dx.doi.org/10.1016/0042-6822(84)90329-5.

48. Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Wakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K. 2007. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 45:1179–1186. http://dx.doi.org/10.1002/hep.21581.

49. Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, Yuan Q, Li PC, Huang Q, Colombo R, Jia J, Hou J, McCrae MA, Gao Z, Ren H, Xia N, Zhuang H, Lu F. 2016. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 65:700–710. http://dx.doi.org/10.1016/j.jhep.2016.05.029.

50. Zhou T, Guo H, Guo JT, Cuconati A, Mehta A, Block TM. 2006. Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 72:116–124. http://dx.doi.org/10.1016/j.antiviral.2006.05.006.